Literature DB >> 7913670

Analysis of c-fos, c-jun, c-erbB1, c-erbB2 and c-myc in primary lung carcinomas and their lymph node metastases.

M Volm1, G van Kaick, J Mattern.   

Abstract

The purpose of this study was to identify possible alterations in proto-oncogenes (c-fos, c-jun, c-erbB1, c-erbB2 and c-myc) at the protein level in primary lung carcinomas and simultaneous metastatic lymph nodes of 21 patients. The analysis showed that proteins of c-jun and c-myc were expressed in a significantly higher frequency in metastases than in primary lung tumors. Gross differences were not found between primary tumors and metastatic tumors with regard to the expression of c-erbB1, c-erbB2 and c-fos. The finding of cases with a higher expression of c-jun and c-myc in lymph nodes suggests that metastatic capability may be higher in certain cell populations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7913670     DOI: 10.1007/bf01753840

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  32 in total

1.  Resistance mechanisms in murine tumors with acquired multidrug resistance.

Authors:  M Volm; T Efferth; J Mattern; E W Pommerenke
Journal:  Arzneimittelforschung       Date:  1992-09

2.  Ploidy of primary and metastatic human tumors.

Authors:  G RABOTTI
Journal:  Nature       Date:  1959-05-02       Impact factor: 49.962

3.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

4.  Expression of oncoproteins in primary human non-small cell lung cancer and incidence of metastases.

Authors:  M Volm; P Drings; W Wodrich; G van Kaick
Journal:  Clin Exp Metastasis       Date:  1993-07       Impact factor: 5.150

5.  Comparison of cellular protooncogene activation and transformation-related activity of human melanocytes and metastatic melanoma.

Authors:  Z Husain; G B FitzGerald; M M Wick
Journal:  J Invest Dermatol       Date:  1990-11       Impact factor: 8.551

6.  Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases.

Authors:  H Lacroix; J D Iglehart; M A Skinner; M H Kraus
Journal:  Oncogene       Date:  1989-02       Impact factor: 9.867

7.  Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.

Authors:  M Volm; M Kästel; J Mattern; T Efferth
Journal:  Cancer       Date:  1993-06-15       Impact factor: 6.860

Review 8.  The pathogenesis of cancer metastasis.

Authors:  G Poste; I J Fidler
Journal:  Nature       Date:  1980-01-10       Impact factor: 49.962

9.  Detection of fos protein during osteogenesis by monoclonal antibodies.

Authors:  P De Togni; H Niman; V Raymond; P Sawchenko; I M Verma
Journal:  Mol Cell Biol       Date:  1988-05       Impact factor: 4.272

10.  p185neu expression in human lung adenocarcinomas predicts shortened survival.

Authors:  J A Kern; D A Schwartz; J E Nordberg; D B Weiner; M I Greene; L Torney; R A Robinson
Journal:  Cancer Res       Date:  1990-08-15       Impact factor: 12.701

View more
  11 in total

1.  Resistance to apoptosis induced by microenvironmental stresses is correlated with metastatic potential in Lewis lung carcinoma.

Authors:  M Takasu; Y Tada; J O Wang; M Tagawa; K Takenaga
Journal:  Clin Exp Metastasis       Date:  1999-07       Impact factor: 5.150

2.  Regulation of activator protein-1 activity in the mediastinal lymph node metastasis of lung cancer.

Authors:  K Ichiki; N Mitani; Y Doki; H Hara; T Misaki; I Saiki
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

3.  MYC and human telomerase gene (TERC) copy number gain in early-stage non-small cell lung cancer.

Authors:  Antonella Flacco; Vienna Ludovini; Fortunato Bianconi; Mark Ragusa; Guido Bellezza; Francesca R Tofanetti; Lorenza Pistola; Annamaria Siggillino; Jacopo Vannucci; Lucio Cagini; Angelo Sidoni; Francesco Puma; Marileila Varella-Garcia; Lucio Crinò
Journal:  Am J Clin Oncol       Date:  2015-04       Impact factor: 2.339

4.  Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice.

Authors:  Shalini Singh; Charles Vinson; Cathy M Gurley; Greg T Nolen; Marjorie L Beggs; Radhakrishnan Nagarajan; Erwin F Wagner; David M Parham; Charlotte A Peterson
Journal:  Am J Pathol       Date:  2010-09-09       Impact factor: 4.307

5.  Applications of CRISPR/Cas technology against drug-resistant lung cancers: an update.

Authors:  Mayank Chaudhary; Pooja Sharma; Tapan Kumar Mukherjee
Journal:  Mol Biol Rep       Date:  2022-09-12       Impact factor: 2.742

6.  Polymorphic nucleic Acid binding of bioactive isoquinoline alkaloids and their role in cancer.

Authors:  Motilal Maiti; Gopinatha Suresh Kumar
Journal:  J Nucleic Acids       Date:  2009-12-15

7.  Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas.

Authors:  M Volm; W Rittgen; P Drings
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

Review 8.  Biomarkers in Exhaled Breath Condensate and Serum of Chronic Obstructive Pulmonary Disease and Non-Small-Cell Lung Cancer.

Authors:  Mann Ying Lim; Paul S Thomas
Journal:  Int J Chronic Dis       Date:  2013-08-01

9.  TAC-101 (4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid) inhibits spontaneous mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma.

Authors:  K Murakami; T Yamaura; K Suda; S Ohie; J Shibata; T Toko; Y Yamada; I Saiki
Journal:  Jpn J Cancer Res       Date:  1999-11

10.  Oxidative and nitrosative stress in the metastatic microenvironment.

Authors:  Angel L Ortega; Salvador Mena; José M Estrela
Journal:  Cancers (Basel)       Date:  2010-03-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.